Related Experiment Video
Updated: Dec 11, 2025

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
NUP98-NSD1 Driven MDS/MPN in Childhood Masquerading as JMML
Astrid Behnert1,2, Alex G Lee1,2, Elizabeth P Young1
1Department of Pediatrics, Benioff Children's Hospital.
Abstract:
Overlapping myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal hematopoietic disorders with features of myelodysplasia and myeloproliferation. The only well-characterized MDS/MPN in children is juvenile myelomonocytic leukemia, an aggressive disorder of infants and toddlers. The biochemical hallmark of this disease is hyperactivation of the Ras/MAPK signaling pathway caused by mutations in Ras pathway genes in more than 90% of patients. Translocations involving receptor tyrosine kinases have been identified in rare cases. Here, we report a 2-year-old patient who presented with MDS/MPN driven by a cytogenetically cryptic NUP98-NSD1 fusion, a translocation thought to exclusively occur in patients with acute myeloid leukemia.
Insights
Juvenile myelomonocytic leukemia (MDS/MPN) in children is typically driven by Ras pathway gene mutations. This study identifies a NUP98-NSD1 fusion, previously seen only in acute myeloid leukemia, as a cause of MDS/MPN in a pediatric patient.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Overlapping myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are rare clonal hematopoietic disorders.
- Juvenile myelomonocytic leukemia (JMML) is the primary MDS/MPN subtype in children, characterized by Ras/MAPK pathway hyperactivation.
- Mutations in Ras pathway genes are found in over 90% of JMML cases, with receptor tyrosine kinase translocations being rare.
Observation:
- A 2-year-old patient presented with clinical and laboratory features of MDS/MPN.
- Genetic analysis revealed a cytogenetically cryptic NUP98-NSD1 fusion in the patient's hematopoietic cells.
Findings:
- The NUP98-NSD1 fusion, typically associated with acute myeloid leukemia (AML), was identified as the driver mutation in this pediatric MDS/MPN case.
- This finding expands the known molecular landscape of pediatric MDS/MPN beyond Ras pathway mutations.
Implications:
- The identification of NUP98-NSD1 in pediatric MDS/MPN suggests a potential new therapeutic target for this aggressive disease.
- This case highlights the importance of comprehensive genetic screening in pediatric myeloid neoplasms, even in the presence of common JMML mutations.
- Understanding novel genetic drivers like NUP98-NSD1 is crucial for accurate diagnosis and the development of targeted therapies in pediatric hematologic malignancies.
More Related Videos
08:22A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations
Published on: December 1, 2017
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
Related Concept Videos
Nonsense-mediated mRNA Decay
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
Differentiation of Common Myeloid Progenitor Cells
Sex-linked Disorders
Inborn Errors of Metabolism
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
Multipotency of Hematopoietic Stem Cells